Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

An Overview on Tumor-Infiltrating Lymphocyte Therapy for Solid Tumors

February 2nd 2023

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

Institutional Perspectives in Cancer: Skin Cancer - Chaired by Faithlore Gardner, MD

January 24th 2023

Institutional Perspectives in Cancer: Skin Cancer - Chaired by Faithlore Gardner, MD

FDA Grants Fast Track Designation to EVX-01 Plus Pembrolizumab in Metastatic Melanoma

January 20th 2023

The FDA has granted a fast track designation to EVX-01 in combination with pembrolizumab for the treatment of patients with metastatic melanoma.

FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Cutaneous Melanoma

January 20th 2023

The FDA has granted an orphan drug designation to LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

Dr. Pavlick on the Benefit of Neoadjuvant Immunotherapy in Resectable Melanoma

January 16th 2023

Anna C. Pavlick, DO, discusses the potential benefit of neoadjuvant immunotherapy prior to surgical resection, according to results from the phase 2 SWOG S1801 trial.

Adjuvant Pembrolizumab Improves QOL vs Ipilimumab or HDI in Resected Melanoma

January 10th 2023

Treatment with adjuvant pembrolizumab resulted in favorable quality-of-life outcomes vs high-dose interferon α 2b or ipilimumab in patients with resected melanoma at high risk for relapse.

Dr. Patel on the Sequencing of Immunotherapy and Targeted Therapy in BRAF-Mutant Melanoma

January 9th 2023

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Dr. Contreras on the Role of Neoadjuvant Pembrolizumab in Desmoplastic Melanoma

January 6th 2023

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

FDA Approval Sought for Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma

January 4th 2023

A biologics license application has been submitted to the FDA seeking the approval of cosibelimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Dr. Verschraegen on the Need for Predictive Biomarkers for Immunotherapy in Melanoma

January 4th 2023

Claire F. Verschraegen, MD, discusses the need for predictive biomarkers for the use of immunotherapy in the treatment of melanoma.

Neoadjuvant Immunotherapy Represents an Improved Option for Resectable Melanoma

December 30th 2022

Anna Pavlick, DO, MBA, discusses key updates from clinical trials that continue to shape the treatment of patients with melanoma, the role of immunotherapy in the frontline setting, and the importance of toxicity management and patient support.

Personalized Immunotherapy Regimens Drive Frontline Melanoma Care

December 29th 2022

Claire F. Verschraegen, MD, discusses how nivolumab and ipilimumab fit into the treatment paradigm, poses examples of when treatment-related adverse effects might influence which agents to use, and emphasizes the importance of considering the benefits of immunotherapy.

Emergence of Tebentafusp Underscores the Need for Additional Advancements in Uveal Melanoma

December 23rd 2022

Richard D. Carvajal, MD, discusses the implications of the FDA approval of tebentafusp in uveal melanoma, the possibility of exploring tebentafusp in other HLA subtypes, and other areas of intriguing research in uveal melanoma.

Melanoma Expert Focuses on Finding the Next Best Therapy

December 22nd 2022

Clinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.

Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials

December 21st 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Dr. Contreras on Neoadjuvant Therapies in Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

December 19th 2022

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Dr. Verschraegen on the Need to Address TRAEs of Immunotherapy in Melanoma

December 9th 2022

Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.

Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received

December 8th 2022

Lifileucel achieved safety and efficacy irrespective of the number of aldesleukin doses administered to patients with advanced melanoma.

Pembrolizumab Appears Safe Across Melanoma, NSCLC, RCC in Pooled Analysis

December 8th 2022

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

RP1 Plus Nivolumab Elicits Responses in Melanoma After Progression on Anti–PD-1 Therapy

December 7th 2022

The combination of vusolimogene oderparepvec and nivolumab generated promising responses in patients with cutaneous melanoma who failed previous anti–PD-1 therapy, according to initial data from the phase 2 IGNYTE trial.